Bilateral Choroidal Metastases In Triple-Negative Breast Cancer: Radiotherapy And Eribulin For Vision Preservation And Prolong Survival

Harissa Husainy Hasbullah, Zulia Zulkiffli, Han Albert Dicken

Abstract


Introduction: Choroidal metastases are infrequent in breast cancer, but if they present, they usually signify the disseminated disease and poor prognosis. The challenges in treating choroidal metastases are not only to prolong survival but also to preserve vision, improving the quality of life.

Case Presentation: Our patient was firstly diagnosed with stage-three triple-negative breast cancer at the age of 32 years. She had surgery, adjuvant chemotherapy with anthracycline regime, as well as adjuvant radiotherapy. Her disease firstly recurred two years later with pleural effusion, but it was controlled with six cycles of docetaxel. She was in remission until ten years later when she presented with a worsening dry cough and progressive blurring of vision in both eyes. CT restaging showed multiple sub-centimeter bilateral lung nodules, singular pleural metastases, and multiple bone metastases. Choroidal metastases were also confirmed with the ophthalmological assessment which includes CT of the orbit. She received short-course palliative radiotherapy followed immediately by eribulin. Then, she started monthly bisphosphonates. She was able to read again four months after radiotherapy, and her vision remains normal to date. The latest PET scans showed no FDG avid disease in the lungs with pleural metastases significantly reduced in size. Bone metastases remain stable and asymptomatic. It has been nearly four years since the diagnosis of choroidal metastases. She is still on eribulin at an adjusted dose and interval. She remains asymptomatic from her bone, lung, and choroidal metastases.

Conclusions: Short-course radiotherapy to the orbit, followed by continuous administration of eribulin, can lead to prolonged survival with a good quality of life in triple-negative breast cancer with choroidal metastases


Keywords


choroidal metastases, eribulin, triple-negative breast cancer

References


Azizah A, Hashimah B, Nirmal K, ET AL. Malaysian National Cancer Registry Report 2012–2016: Malaysia Cancer Statistic, Data and Figure [Internet]. Malaysia: National Cancer Institute; 2019 [cited 2021 October 30]. Available from: https://www.moh.gov.my/moh/resources/Penerbitan/Laporan/Umum/2012-2016%20(MNCRR)/MNCR_2012-2016_FINAL_(PUBLISHED_2019).pdf

National Cancer Institute Ministry of Health Malaysia. Malaysian Study on Cancer Survival [Internet]. Putrajaya: National Cancer Institute Ministry of Health Malaysia; 2018 [cited 2021 October 30]. Available from: http://nci.moh.gov.my/index.php/ms/main-menu-2/ laporan

Mathis T, Jardel P, Loria O, et al. New concepts in the diagnosis and management of choroidal metastases. Prog Ret Eye Res. 2019;68:144-76.

Vlachostergios PJ, Voutsadakis IA, Papandreou CN. Orbital metastasis of breast carcinoma. Breast Cancer (Auckl). 2009;3:91-97.

Daoudi S, Touimi SH, Adrif I, et al. Ocular metastasis from breast cancer: case report. World J Innov Res. 2020;8(4):10-12.

Demirci H, Shields CL, Chao AN, Shields JA. Uveal metastasis from breast cancer in 264 patients. Am J Ophthalmology. 2003;136(2):264-71.

Mohammad J, Karthiga S, Khaled AQ, et al. Choroidal metastases from breast carcinoma: case series. Pan Arab J Oncol. 2011;4(1):6-10.

Cárdenas JRV, Penella ADV, Ibarra EC. Frameless radiosurgery for intraocular metastatic tumor: Case report. Rep Pract Oncol Radiother. 2020;25(1):1-5.

Rudoler SB, Corn BW, Shields CL, et al. External beam irradiation for choroid metastases: identification of factors predisposing to long-term sequelae. Int J Radiat Oncol Biol Phys. 1997;38(2):251-6.

Youbi ZA, Ciprian E, Ionela C, et al. Management of choroidal metastasis using external beam radiotherapy: a retrospective study and review of the literature. J Cancer Metastasis Treat. 2017;3:105-10.

Wong ZW, Phillips SJ, Ellis MJ. Dramatic response of choroidal metastases from breast cancer to a combination of trastuzumab and vinorelbine. Breast J. 2004;10(1):54-6.

Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. The Lancet. 2011;377(9769):914-23.

Twelves C, Cortes J, Vahdat L, et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat. 2014;148(3):553-61.

Ricciardi GR, Proto C, Ferraro G, Adamo V. Uncommon breast metastatic site and eribulin responsiveness in a heavily pretreated patient. Future Oncol. 2014;10(15):2417-22.

Kaufman PA, Awada A, Twelves C, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015;33(6):594-601.

Sirvén MB, Fernández-Ortega A, Stradella A, et al. Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center BMC Pharmacol Toxicol. 2019;20(1):1-7.


Full Text: PDF

DOI: 10.33371/ijoc.v15i4.857

Article Metrics

Abstract view : 37 times
PDF - 24 times

Refbacks

  • There are currently no refbacks.


Copyright (c) 2021 Indonesian Journal of Cancer

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.